Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Dec 14, 2016
- Genocea's ATLAS technology to profile the T cell responses of patients enrolled in ongoing Phase 1b CMP-001/pembrolizumab clinical trial against library of common melanoma antigens - - Collaboration aims to identify antigens associated with therapeutic T cell responses - CAMBRIDGE, Mass., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Genocea Bio...
Dec 8, 2016
CAMBRIDGE, Mass., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, will host a virtual Research and Development (R&D) Day for analysts, investors and media on Wednesday, December 14, 2016, starting at 8:30 a.m. ET. This event will be ava...
Nov 11, 2016
- ATLAS discovers neoantigens, through functional T cell responses, which were not identified by predictive algorithms - - Majority of antigens predicted by algorithms not biologically relevant in ATLAS assays - - Data to be presented at 2016 SITC Annual Meeting - CAMBRIDGE, Mass., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, In...
Nov 9, 2016
CAMBRIDGE, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at two upcoming investor conferences in November: Stifel 2016 Healthcare Conference: Corporate presen...
Nov 3, 2016
- Positive Phase 2b results recently reported and dose selected for GEN-003 Phase 3 program expected to initiate in 2H 2017 - - Conference Call at 9am ET today - CAMBRIDGE, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a company developing T cell-directed vaccines and immunotherapies, today reported corp...
Oct 28, 2016
- Increase in CD4+ polyfunctional T cells indicates GEN-003 is stimulating a multi-faceted T cell immune response to genital herpes - - GEN-003 elicited strong antibody responses at 12 months post-dosing - CAMBRIDGE, Mass., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a company developing T cell-directed vacci...
Oct 27, 2016
CAMBRIDGE, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, November 3, 2016 at 9:00 a.m. ET to discuss financial results for the third quarte...
Sep 29, 2016
- Trial achieves primary endpoint - - Dose confirmed for subsequent trials -   - Phase 3 expected to start in 2H 2017 - - Company to host conference call at 9 a.m. ET today - CAMBRIDGE, Mass., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immu...
Aug 9, 2016
CAMBRIDGE, Mass., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, is delighted to congratulate Jessica Baker Flechtner, Ph.D., chief scientific officer, who was acknowledged as an honoree on this year's 40 Women to Watch Over 40 list. T...
Aug 4, 2016
CAMBRIDGE, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today reported corporate highlights and financial results for the second quarter ended June 30, 2016. "Full results from the Phase 2 dose optimization trial evaluati...
Jul 28, 2016
CAMBRIDGE, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, August 4, 2016 at 9:00 a.m. ET to discuss financial results for the second quarter...
Jul 6, 2016
CAMBRIDGE, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the upcoming Cantor Fitzgerald 2nd Annual Healthcare Conference on Wednesday, July 13, 2016 at 3:00 p.m...
Jun 9, 2016
CAMBRIDGE, Mass., June 09, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Ron Cooper has joined its board of directors, effective immediately. Mr. Cooper currently serves as president and chief executive officer at Albireo ...
Jun 9, 2016
- Presentation of GEN-003 12-Month Data Featured in ASM Press Briefing - - Phase 2 GEN-004 Results Highlight Potential for Future Development of Vaccine for Pneumococcal Disease - CAMBRIDGE, Mass., June 09, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and i...
May 23, 2016
CAMBRIDGE, Mass., May 23, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that John E. Bishop, Ph.D. has joined the company as senior vice president of pharmaceutical sciences. "I am delighted to welcome John to Genocea at s...
= add release to Briefcase